Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003903 · ClinicalTrials.gov registry record · NA
Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer
A NA study, sponsored by University of Rochester.
- Completed
- Registry status
- NA
- Development phase
- 150
- Enrollment target
NCT00003903 is a NA study that has completed, run by University of Rochester. The registered enrollment target is 150 participants.
The verdict
NCT00003903, a NA study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
Study Summary
RATIONALE: Assessing the effect of androgen suppression on bone loss in prostate cancer patients may improve the ability to plan treatment, may decrease the risk of fractures and bony pain, and may help patients live more comfortably. PURPOSE: Clinical trial to determine the effect of androgen suppression on bone loss in patients who have prostate cancer.
Interventions
- PROCEDURE management of therapy complications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 1999-07 |
| Est. Completion | 2007-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003903
The ClinicalTrials.gov registry entry for NCT00003903 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which management of therapy complications is the first listed.
NCT00003903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003903 about?
NCT00003903 is a clinical study titled "Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer". RATIONALE: Assessing the effect of androgen suppression on bone loss in prostate cancer patients may improve the ability to plan treatment, may decrease the risk of fractures and bony pain, and may help patients live more comfortably. PURPOSE: Clinical trial to determine the effect of androgen supp...
What is the current status of trial NCT00003903?
This trial is currently completed. It is a NA study. The enrollment target is 150 participants. The study started on 1999-07. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00003903?
The interventions under investigation include: management of therapy complications (PROCEDURE).
Who is sponsoring clinical trial NCT00003903?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.